Mineralcorticoid Receptor
Showing 1 - 25 of 7,083
COVID-19 Acute Respiratory Distress Syndrome Trial (Potassium Canrenoate)
Not yet recruiting
- COVID-19 Acute Respiratory Distress Syndrome
- Potassium Canrenoate
- (no location specified)
May 16, 2022
Heart Failure, Hyperkalemia Trial in Gothenburg (Sodium zirconium cyclosilicate, Placebo)
Recruiting
- Heart Failure
- Hyperkalemia
- Sodium zirconium cyclosilicate
- Placebo
-
Gothenburg, SwedenSahlgrenska University Hospital-Ostra Hospital
Sep 20, 2021
Healthy Volunteers Trial in Miami, South Miami (Eplerenone or Placebo)
Completed
- Healthy Volunteers
- Eplerenone or Placebo
-
Miami, Florida
- +1 more
Dec 19, 2020
Heart Failure With Mid-range Ejection Fraction, Heart Failure With Preserved Ejection Fraction Trial in Worldwide (Experimental:
Recruiting
- Heart Failure With Mid-range Ejection Fraction
- Heart Failure With Preserved Ejection Fraction
- Experimental: Spironolactone
- Placebo Comparator
-
Graz, Austria
- +68 more
Jan 28, 2021
Thrombopoietin Agonists in Idiopathic Thrombocytopenic Purpura
Not yet recruiting
- ITP - Immune Thrombocytopenia
- eltrombopag and romiplastim
- (no location specified)
Nov 16, 2023
Breast Tumors Trial in Beijing, Nanjing, Changsha (Disitamab Vedotin, Toripalimab)
Not yet recruiting
- Breast Neoplasms
- Disitamab Vedotin
- Toripalimab
-
Beijing, Cancer Hospital Chinese Academy Of Medical Sciences, China
- +2 more
Oct 23, 2023
Natural Killer T Cells ExpressingInvariant T Receptor :
Not yet recruiting
- Systemic Lupus Erythematosus
- Physiopathology
- Blood sample
-
Tours, FranceUniversity Hospital
May 12, 2023
Breast Cancer Stage IV Trial in Irvine (Gallium-68)
Recruiting
- Breast Cancer Stage IV
-
Irvine, CaliforniaHoag Memorial Hospital Presbyterian
May 26, 2023
Digestive System Neuroendocrine Tumor G1, Digestive System Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine
Not yet recruiting
- Digestive System Neuroendocrine Tumor G1
- +5 more
- Tumor Debulking
- +5 more
-
Nashville, TennesseeVanderbilt University/Ingram Cancer Center
Aug 23, 2023
Recurrent Glioblastoma Trial (Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T
Not yet recruiting
- Recurrent Glioblastoma
- Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T cell injection
- (no location specified)
Apr 4, 2023
Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer Trial in Worldwide (Samuraciclib, Elacestrant DiHCl)
Recruiting
- Metastatic Breast Cancer
- +2 more
- Samuraciclib
- Elacestrant Dihydrochloride
-
Orange City, Florida
- +27 more
Jul 19, 2023
Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer Trial in Ocala (Samuraciclib, Fulvestrant)
Recruiting
- Metastatic Breast Cancer
- +2 more
-
Ocala, FloridaOcala Oncology Center PL DBA Florida Cancer Affiliates
Jul 19, 2023
Breast Cancer Trial (Trastuzumab Deruxtecan)
Not yet recruiting
- Breast Cancer
- Trastuzumab Deruxtecan
- (no location specified)
Jul 10, 2023
Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation Trial in Peking (Pembrolizumab, pemetrexed,
Not yet recruiting
- Non Small Cell Lung Cancer
- +2 more
- Pembrolizumab, pemetrexed, platinum
- Osimertinib
-
Peking, ChinaPeking Union Medical College Hospital
Nov 16, 2023
Breast Cancer. Real Clinical Practice in Russia
Recruiting
- Breast Cancer
- Neoadjuvant Endocrine Therapy
- Tamoxifen 20mg
- +4 more
-
Moscow, Russian FederationBlokhin's Russian Cancer Research Center
Apr 5, 2023
Ribociclib in Combination With Hormonal Therapy in HR+/HER2-
Not yet recruiting
- Breast Cancer
- ribociclib
- (no location specified)
Oct 10, 2023
MDD (MDD) Trial (HS-10353 30mg oral capsules, HS-10353 50mg oral capsules, Placebo for HS-10353 30mg capsules)
Not yet recruiting
- Major Depressive Disorder (MDD)
- HS-10353 30mg oral capsules
- +3 more
- (no location specified)
Jul 10, 2023
Preemptive Analgesia, Dexmedetomidine, Ketamine Trial in Kafr Ash Shaykh (Dexmedetomidine, Ketamine, Magnesium sulphate)
Not yet recruiting
- Preemptive Analgesia
- +5 more
- Dexmedetomidine
- +2 more
-
Kafr Ash Shaykh, Karelsheikh, EgyptKarelsheikh University Hospital
Apr 19, 2023
Compare Overall Survival in Medicare Metastatic Breast Cancer
Active, not recruiting
- Breast Cancer
- Palbociclib
- Aromatase Inhibitor
-
New York, New YorkPfizer New York
Oct 11, 2023
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Trial (Giredestrant, Fulvestrant, Abemaciclib)
Not yet recruiting
- Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Giredestrant
- +6 more
- (no location specified)
Sep 26, 2023
HR+/HER2- Advanced Breast Cancer, Targeted Therapy Trial in Beijing (Everolimus, Chidamide, Endocrine therapy)
Recruiting
- HR+/HER2- Advanced Breast Cancer
- Targeted Therapy
- Everolimus
- +3 more
-
Beijing, Beijing, ChinaNational Cancer Center/National Clinical Research Center for Can
Aug 1, 2023
Hormone Receptor Positive HER-2 Negative Breast Cancer Trial in Shanghai (Docetaxel, Carboplatin, Epirubicin)
Recruiting
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- Docetaxel
- +3 more
-
Shanghai, Shanghai, ChinaBreast cancer institute of Fudan University Cancer Hospital
Jun 12, 2023